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Abstract 
Tetrahydrocurcumin (THC) also referred to as “white curcumin”, is a stable colourless 
hydrogenated product of curcumin with superior antioxidant and anti-inflammatory properties. 
Present study is an attempt to elevate the topical bioavailability of THC, post incorporation into a 
nano-carrier system with its final dosage as a hydrogel. Lipid nanoparticles of THC (THC-SLNs) 
prepared by microemulsification technique were ellipsoidal in shape (revealed in TEM) with a 
mean particle size of 96.6 nm and zeta potential of -22 mV. Total drug content and entrapment 
efficiency of THC-SLNs was 94.51% ± 2.15% and 69.56% ± 1.35 %, respectively. DSC and X-
Ray diffraction studies confirmed the formation of THC-SLNs. In vitro drug release studies 
showed the drug release from THC-SLNs gel to follow Higuchi’s equation revealing a Fickian 
diffusion. Ex-vivo permeation studies indicated a 17 times (approximately) higher skin permeation 
of THC-SLNs gel as compared with the free THC gel. Skin irritation, occlusion and stability 
studies indicated the formulation to be non-irritating, and stable with a desired occlusivity. 
Pharmacodynamic evaluation in an excision wound mice model clearly revealed the enhanced 
anti-inflammatory activity of THC-SLNs gel and confirmed using biochemical and 
histopathological studies. It is noteworthy to report here that THC-SLNs gel showed significantly 
better (p≤0.001) activity than free THC in gel. As inflammation is innate to all the skin disorders, 
the developed product opens up new therapeutic avenues for several skin diseases. To best of our 
knowledge, this is the first paper elaborating the therapeutic usefulness of white curcumin loaded 
lipidic nanoparticles for skin inflammation. 
Keywords: Tetrahydrocurcumin; skin inflammation; solid lipid nanoparticles (SLNs); 
bioavailability; histopathology; occlusion; ex-vivo permeation 
 
Introduction 
Curcumin, a yellow coloured polyphenolic compound derived from the rhizome of the herb 
Curcuma longa L, has been characterized as an excellent molecule among many naturally 
occurring compounds, for treatment of several skin inflammatory conditions like atopic 
dermatitis1-3. It alleviates the skin conditions by mode of antioxidant and anti-inflammatory actions 
in addition to wound repairing capabilities4-6. However, inspite of its proven efficacy and safety, 
it has not yet been approved as a therapeutic agent and till date no commercialisation is in pipeline. 
Major limitations to the latter are its low bioavailability assigned to it poor aqueous solubility (11 
ng/mL) especially at acidic and physiological pH, higher log P value of 3.29, and instability at 
physiological pH (7.4) and in the presence of light7.  In this regard, several nanotechnology based 
drug delivery systems are being developed.  These include polymeric nanoparticles8, solid lipid 
nanoparticles9-11, liposomes12, and microemulsions13,14. However, a major problem associated with 
the topical application of curcumin is the yellow stain left on the skin post application.  
Tetrahydrocurcumin (THC), a metabolite of curcumin is prophesied beneficial for local treatments 
in the gut15-17. It is an excellent antioxidant molecule which possesses superior stability at 
physiological pH (7.4)18 and in plasma, in addition to being colourless. Moreover, THC is reported 
to possess an anti-inflammatory activity better than curcumin18. THC is however an underexplored 
molecule for its application in topical disorders though a few reports do indicate its use in cosmetic 
preparations as a depigmenting agent19.  Due to its poor aqueous solubility (0.0056 mg/mL) and a 
log P value of 2.98, THC could be expected to be a poor skin permeant20,21. 
Nano-couturing of phytochemicals, has been evidenced to result in bioavailable formulations as a 
result of improved solubility and stability. Conventional topical treatment using ointments or 
creams requires frequent application and has shown variable patient responses which results in 
reduced patient compliance. Nanoparticles based drug delivery systems (e.g., liposomes, nano and 
microemulsions and lipid nanoparticles) have received particular attention for their ability to 
improve penetration across stratum corneum and for their specific targeting properties22. 
Drug loaded lipid based nanoparticles in form of a dispersion or post incorporation into a hydrogel, 
ointment or a cream base have shown advantages like increased bioavailability, physical stability, 
protection of incorporated thermolabile drugs from degradation and controlled release23-25. 
Present study is an attempt to improve the topical bioavailability of THC, post incorporation into 
a nano-carrier system(s) with its final dosage as a hydrogel. SLNs, were prepared using a 
spontaneous, feasible and lab scalable microemulsification technique. THC-SLNs dispersion was 
evaluated for particle size, polydispersity index (PI), zeta potential, total drug content, entrapment 
efﬁciency and TEM. DSC and X-ray diffraction studies were performed to confirm the formation 
of THC-SLNs. In vitro drug release via SLNs was carried out using dialysis membrane. Further, 
THC-SLNs hydrogel was evaluated for pH, rheological characteristics, and  occlusivity 
measurements were also carried out. These were followed by skin irritancy (OECD 404) and ex-
vivo permeation studies in animals. Stability studies were performed on the THC-SLNs and its 
hydrogel in accordance to ICH guidelines Q1A (R2). Finally, the proof of concept studies in an 
excision wound mice model of inflammation was performed. As inflammation is innate to most of 
the skin disorders, it was proposed to evaluate its efficacy in an excision wound mice model, 
wherein the role of oxidative stress in addition to inflammation has been indicated.  Post topical 
application, efficacy of THC-SLNs gel in terms of antioxidant balance and anti-inflammatory 
activity was determined. Though ample research on nanotechnological intervention on curcumin 
has been reported and published by us and other scientists working in this area, however, white 
curcumin has remained as an unexplored molecule. To the best of our knowledge this is the first 
paper elaborating the therapeutic usefulness of white curcumin for skin inflammation with superior 
properties of providing a cosmetic elegance to the product owing to its colorless and non-staining 
nature in addition to being a better anti-oxidant and an anti-inflammatory agent.  
Material and methods 
Materials 
Tetrahydrocurcumin was a generous gift sample from Sanat Pharmaceuticals Ltd. (New Delhi, 
India). Carbopol® 934, disodium hydrogen phosphate, sodium carbonate, sodium dihydrogen 
phosphate and tween 80 were obtained from Central Drug House (P) Ltd. (New Delhi, India). 
Compritol® 888ATO was obtained as gift sample from Panacea Biotec (Lalru, Punjab). 
Chloroform and diethyl ether were purchased from Sisco Research Laboratories (Mumbai, India). 
Ethylene diamine tetra acetic acid and triethanolamine were supplied by SD Fine Chemicals 
(Mumbai, India). Formalin and hydrochloric acid were obtained by Qualigens Fine Chemicals 
(Mumbai, India). Ellman reagent was purchased from Himedia Laboratories Ltd. (Mumbai, India). 
Methanol and polyethylene glycol were obtained from Fisher Scientific (Mumbai, India). Ethanol 
was obtained from Changshu Yanguan Chemicals (China). Phospholipon G was procured as a gift 
sample from Gattefosse SAS, France.  
Preparation of THC-SLNs 
THC loaded SLNs were prepared by microemulsification method26. Briefly, tween 80 (30%), 
phosphatydylcholine (PC) (2%) and water were placed together in a beaker and heated to the lipid 
melting temperature. Compritol® 888 ATO (7.27%) was also melted at 82-85°C separately. THC 
(0.2%) was added to the aqueous phase, following which the hot aqueous emulsifier mix, was 
dropped at once into the lipid melt, under magnetic stirring to obtain a clear microemulsion. The 
hot microemulsion thus formed, was transferred into an equivalent amount of cold water (2°C) 
under continuous mechanical stirring (5000 rpm) for 1.5 hour. In the aqueous medium, SLNs were 
formed by crystallization of the lipid droplets present in the microemulsion. 
Incorporation of THC-SLNs into a hydrogel system 
For improving the acceptability and patient compliance, prepared THC-SLNs were incorporated 
into a hydrogel base. Latter is purported to improve the spreadability of the prepared SLNs 
dispersion on topical application. Carbopol® 934 (500 mg) was dispersed in 25 mL of water and 
kept overnight for swelling. Triethanolamine (0.75 g) was added to this mixture with continuous 
stirring, to effect gelling of Carbopol® 934. Stirring was continued until a translucent gel was 
formed. Then, 25 mL of THC-SLNs dispersion was added to the prepared gel and mixed slowly 
to obtain a homogenous mixture containing 1% w/v of Carbopol® 934 and 0.2% w/w concentration 
of THC. Free drug gel comprising of Carbopol® 934 (1% w/v) was prepared by incorporation of 
similar THC concentration (0.2% w/w) as contained in THC-SLNs. We wish to highlight here that 
as THC is not soluble in water, the addition of the drug into the gel base, though produced a non-
homogeneous mixture, in comparison to gel of THC-SLNs, however, it was subjected to 
homogenization to ensure a uniform distribution of drug in the gel. 
Characterization of THC-SLNs and THC-SLNs loaded hydrogel 
Particle analysis 
The mean diameters of THC-SLNs in the dispersion and blank SLNs were measured with 
appropriate dilutions with distilled water (1:20) using DelsaTM Nano C (Beckman Coulter, 
California, USA). It is based on photon correlation spectroscopy, which determines particle size 
by measuring the rate of fluctuations in laser light intensity scattered by particles as they diffuse 
through a fluid. 
 
Zeta potential 
Zeta potential was determined by using DelsaTM Nano C (Beckman Coulter, California, USA). It 
measures the electrophoretic movement of the particles under an applied electric field from the 
doppler shift of scattered light at 25 ᵒC.  
Transmission electron microscopy (TEM) 
THC-SLNs were observed microscopically using TEM (H-7500, Hitachi Ltd., Japan) for 
uniformity of size, shape and physical stability characteristics i.e. aggregation or irregularity, at an 
accelerated voltage of 80 kV. A drop of the sample appropriately diluted (1/20) was placed on a 
carbon-coated copper grid to leave a thin film on the grid.  Excess of the solution was drained off 
with a filter paper. The grid was air dried thoroughly and samples were viewed under TEM 
(20000x and 200000x), for various morphological attributes and particle size. 
Total drug content (TDC) and entrapment efficiency (EE) 
Total drug content (TDC) of THC-SLNs dispersion and THC-SLNs gel was determined by 
disrupting 1 ml of dispersion and 1 g of gel using mixture of chloroform: methanol (1:1). Latter 
was centrifuged at 5000 rpm to obtain a clear solution which was filtered (0.2 µm) and analysed 
spectrophotometrically at λmax of 282 nm using chloroform: methanol (1:1) as blank. Total drug 
content was calculated from the standard calibration curve.  
The entrapment efficiency (EE) of the prepared THC-SLNs dispersion and THC-SLNs hydrogel 
was determined by using a dialysis membrane having pore size 2.4 nm, molecular weight cut off 
12–14 Kda. Membrane was soaked in double-distilled water for 12 hours prior to use. The SLNs 
dispersion (1 mL) and the hydrogel (1 g) was placed in this pre-soaked dialysis tubing, which was 
hermetically sealed, and dialyzed against methanol (50 mL) at room temperature for 45 minutes. 
The amount of drug released into the receptor/release medium was analysed 
spectrophotometrically with appropriate dilutions. The SLNs and hydrogel retained in the dialysis 
bag were disrupted using mixture of chloroform and methanol (1:1) to calculate the amount of 
drug entrapped within THC-SLNs and its hydrogel27. Entrapment efficiency was calculated using 
the following expression. 
𝐸𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡	𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦	(%) = 𝐸𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑	𝑑𝑟𝑢𝑔	𝑐𝑜𝑛𝑡𝑒𝑛𝑡	(𝑚𝑔)𝐴𝑐𝑡𝑢𝑎𝑙	𝑑𝑟𝑢𝑔	𝑐𝑜𝑛𝑡𝑒𝑛𝑡	(𝑚𝑔) × 100 
Differential scanning calorimetry (DSC) 
DSC was performed with a Perkin-Elmer Differential Calorimeter. DSC is a tool to investigate the 
melting and recrystallization behaviour of crystalline materials like SLNs. The breakdown or 
fusion of the crystal lattice by heating or cooling the sample yields information about the internal 
polymorphism, crystal ordering, or glass transition processes. It uses the fact that different lipid 
modifications possess different melting points and enthalpies. The thermal analysis of the pure 
drug, lipid, physical mixture and THC-SLNs was done to observe for any significant changes in 
the pattern of the peaks. Samples were placed in a conventional aluminium pan and heated from 
10◦C to 250◦C at a scan speed of 10 ◦C/minutes28. 
X-ray diffraction studies (XRD) 
XRD is an advanced and potential technique based on scattered intensity of an X-Ray beam, hitting 
a sample as a function of incident and scattered angle, polarization and wavelength or energy. The 
versatility and non-destructive operational procedures of the technique exhibits the 
crystallographic structure of the raw samples with its finished products29. 
Powder X-Ray diffraction patterns of THC-SLNs, lipid and pure drug were recorded using 
XPERT-PRO diffractometer system, using Cu, Kα and Kβ radiations at 45 kV, 40 mA and a 
temperature of 25 ᵒC. The samples were analyzed between 2Ɵ angles of over 5-50 ᵒC.  
 
Determination of pH and rheology 
pH of the gel was determined using glass electrode pH meter (Pico+, Lab India). Rheology of the 
prepared gel was determined using cone and plate type rheometer (Rheolab QC, Anton Paar 
GmbH, Vienna, Austria) attached with water jacket (C-LTD80/QC) for maintaining constant 
temperature. Data analysis was carried out using Rheoplus/32 version 3.40. ACC27 spindle 
geometry was used for measuring the torque as well as viscosity of the sample. Temperature was 
kept at 30 ᵒC and shear rate was selected from 0 to 100 s-1. 
Other rheological characteristics i.e. stickiness and force of extrusion of the formulation were 
evaluated using TTC spreadability rig, fitted on texture analyzerTM (M/s stable micro systems ltd., 
UK). Approx. 10 g of formulation was placed into the lower cone of the instrument and pressed to 
remove any air pockets (entrapped air). Excess formulation was scrapped off to leave a flat test 
area. 
Before testing, the upper cone probe was calibrated against lower cone so that the starting point 
was at same height for each test approx 25 mm above to lower cone. During testing the upper 
conical probe penetrated into the sample and continued to a depth of 2 mm above the sample holder 
surfaces i.e. probe moved a distance of 23 mm from its starting point (test speed 3 mm/sec). The 
force encountered by the upper cone probe to break away from gel when starting to ascend (the 
point of maximum force) was taken as the measurement of gel strength; the higher the value, better 
is the strength of gel network. The area of the curve upto this point was taken as measurement of 
work of shear, reflecting the work of spreadability of the sample. The negative region of the graph, 
produced on the return of the probe, was a result of the weight of the sample which is lifted 
primarily on the upper surface of the cone. Latter is evident due to its back movement and hence 
provides an indication of adhesion or resistance to flow off the disc. The maximum negative region 
of the curve was taken as work of adhesion of the gel and it represents the force required to extrude 
from the tube. 
Occlusion testing 
The occlusive properties of THC-SLNs gel, Tacroz® Forte, blank SLNs gel and blank gel without 
SLNs (n = 3) were evaluated by in vitro occlusion test30. Preweighed beakers (100 mL each) with 
an internal diameter of 4.9 cm were taken and filled with 50 mL of water and subsequently covered 
with Whatman filter paper. The formulations were uniformly spread evenly on the surface using a 
spatula. The beakers were then stored at 32 ± 0.5 °C (to mimic the temperature of the skin surface) 
for 48 hours. Beakers were weighed at 24, and 48 hours. The percent water loss was quantified 
and occlusion factor (F) was calculated by the following Equation. 
	𝐹 = 𝐴 − 𝐵	𝐴 	× 100 
 
Where F is the occlusion factor, A is the water loss without sample (reference) and B is the water 
loss with sample. 
 
Stability studies 
The stability studies were performed in accordance to the ICH guidelines31. THC-SLNs dispersion 
was kept at 4 ᵒC ± 3 ᵒC and 40 ºC ± 2 ºC/75% RH ± 5% RH while THC-SLNs gel was stored at 25 
ºC ± 2 ºC/60% RH ± 5% RH and 40 ºC ± 2 ºC/75% RH ± 5% RH respectively and were analysed 
for total drug content, entrapment efficiency, particle size, and visual changes for 0-2 months. 
Further, long term stability studies are planned to be carried out.  
In-vitro drug release 
In-vitro drug release was performed using dialysis membrane having pore size 2.4 nm, molecular 
weight cut off 12–14 Kda. The membrane was equilibrated using the release media (2% tween 80 
+ 10% ethanol + 15% isopropyl alcohol buffer in phosphate buffer pH 7.4) prior to the experiment. 
The media (50 mL) was stirred at 50 rpm throughout the experiment, using a magnetic stirrer. 
Temperature was maintained at 32 ± 0.5 ⁰C during the whole experiment. THC-SLNs dispersion 
(0.25 mL), THC-SLNs gel (500 mg), free THC in gel (500 mg), all containing 940 µg of THC 
were loaded on the dialysis membrane. Samples (3 mL) were withdrawn at 15 minutes, 30 minutes, 
1, 2, 4, 6, 8, 10, 12, and 24 hours. Volume of sample withdrawn was replaced with an equal volume 
of fresh receptor medium. The experiments were carried out for 24 hours. All measurements were 
done in triplicate at 282 nm. The mechanism of drug release was determined by ﬁtting the release 
data to several release kinetic models. 
Ex-vivo skin permeation studies 
Jacketed Franz glass diffusion cells were used for the determination of permeability of THC and 
its SLNs formulations through pig ear skin. Pig ears were obtained post-sacrifice from a local 
abattoir before the pig carcass was exposed to the normal high-temperature cleaning procedure. 
The subcutaneous fat tissue was removed, and hair present was trimmed carefully as short as 
possible using scissors without damaging or scratching the surface in order to ensure the integrity 
of the skin barrier. The barrier integrity of the skin was checked by measuring the transepidermal 
water loss32 and criteria for inclusion/exclusion of the skin sample for the studies was set. Excised 
skin was then carefully mounted on the diffusion cell33. These cells consist of the donor and the 
receptor chambers between which the skin is positioned. Average area of skin in contact with the 
receptor medium was 3.14 cm2 and the average receptor chamber volume was 30.0 mL. Circular 
ear skin pieces equal to or slightly greater than the size of external circumference of donor 
compartment were cut out (n = 6) and mounted onto the diffusion cell assembly, keeping the 
stratum corneum side towards the donor compartment and the dermal side in contact with the 
receptor fluid. The whole system was water jacketed and thermostatically controlled by an external 
circulating water bath at 32 ± 0.5 oC. The receptor media (2% tween 80 + 10% ethanol + 15% 
isopropyl alcohol buffer in phosphate buffer pH 7.4) was stirred at 50 rpm throughout the 
experiment, using a magnetic stirrer. Mounted skin was allowed to equilibrate for 2 hours, after 
which the receptor media was replaced with fresh media. This was done to remove any water 
soluble UV absorbing materials present in or released from the skin, which could interfere with 
the UV spectrophotometric readings of the drug. THC-SLNs dispersion (0.25 mL), THC-SLNs 
hydrogel (500 mg), THC gel (500 mg), all containing 940 µg of THC along with their  respective 
blank formulations were applied evenly onto the donor side of the skin surface and the donor cell 
was covered with aluminium foil to prevent losses due to evaporation. 1.0 mL aliquots were 
withdrawn from the receptor compartment, at different time intervals starting at 15 minutes, 30 
minutes, 1, 2, 4, 6, 8, 10, 12, and 24 hours. The volume of sample withdrawn was replaced with 
an equal volume of fresh receptor medium. The experiments were carried out in triplicate for 24 
hours.  
At the end of permeation studies (24 hours), the skin surface was wiped with a moist cotton swab 
several times (6 times) to remove any residual formulation sticking to the skin. The cotton swabs 
were then put into 10 mL of methanol and vortexed to solubilise and determine the amount of drug 
left on the skin by measuring the absorbance of this solvent after filtration at 282 nm. The skin 
was cut into small pieces and kept in methanol (50 mL) for 24 hours for extraction of the drug in 
the solvent. Latter was then centrifuged and filtered prior to the estimation of drug content by UV 
spectrophotometer at 282 nm (linearity range 0.5-20 µg/mL). Similar procedure was repeated for 
blank (skin without any formulation) so as to determine the amount of drug permeated across 
stratum corneum. 
The flux was obtained by plotting the cumulative amount of drug(s) in the receptor phase/sq. cm. 
of the skin against time. Steady state slope obtained by linear regression of cumulative 
amount/sq.cm versus time plot gives the flux value. 
Acute dermal irritation studies 
Acute dermal irritation study was performed in accordance with the OECD guideline 40431. 
Rabbits (Albino) were divided into two groups (n = 3). One served as control, while the other 
served as treatment group. 
For the preparation of the animals, approximately 24 hours before the test, furs of the animals were 
removed by closely clipping the dorsal area of the trunk of the animals. Care was taken to avoid 
abrading the skin, and only the animals with healthy, intact skin were used. 
Animals were housed individually and were exposed to normal day light cycle. For feeding, 
conventional laboratory diet was used with an unrestricted supply of drinking water. 
Test procedure 
Application of the test substance (THC-SLNs gel) 
 THC-SLNs gel (0.5 g) was applied to a small area (approximately 6 cm2) of skin. At the end of 
the exposure period, which was 4 hours, residual test substance was removed. Scores for erythema 
and oedema were recorded in accordance to the scoring system referred in the guidelines34. 
In vivo pharmacodynamic activity  
Male lacca mice bred in Central Animal House facility of Panjab University, Chandigarh, 
weighing 20-40 g were used. The animals were housed under standard light/ dark cycle with food 
and water provided ad libtum. Animals were acclimatized to laboratory condition before test. The 
experiments were performed between 09.00 and 17.00 hours. The experimental protocol was 
approved by the Institutional Animal Ethics Committee of the institute (PU/IAEC/S/14/59).  
Excision wound mice model 
The animals were divided into 5 groups (n = 6) (Table 1).  The fur of the animals was removed 
and skin was sterilised using 70% alcohol. The animals were anaesthetised using ether. Further, a 
full thickness excision wound of 1 cm diameter was made using sharp scissors. Topical treatment 
with the formulation was started from day 2. The observations were made for visual changes 
starting from initiation of treatment (2nd day) till the final day (14th day) of observation35 and 
percentage wound closure was determined by the formula. 𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒	𝑤𝑜𝑢𝑛𝑑	ℎ𝑒𝑎𝑙𝑖𝑛𝑔 = ABCDCEF	EGHEIBDJ	KEL	EGHE	×MNNABCDCEF	EGHE . 
 
Biochemical estimation 
Preparation of tissue homogenate 
At the end of 14th day, the mice were sacrificed by ether inhalation. Mice skin was excised and 
rinsed in ice cold phosphate buffer saline (pH 7.4). The homogenate  of the skin 8% (g of skin in 
volume of phosphate buffer saline) was prepared using tissue homogenizer at 5,000 rpm. It was 
then, centrifuged at 10,000 rpm at 4oC for 10 minutes and the clear supernatants were collected 
and used for the following biochemical estimations of various groups. Protein estimation was 
performed using biuret test36. Lipid peroxidation, reduced glutathione estimation, superoxide 
dismutase and catalase activity was performed according to the standard referred methods37,38. 
Histopathological studies 
After 14thday of the treatment protocol, the animals were sacrificed by ether anaesthesia and treated 
dorsal area was excised, rinsed with ice cold phosphate buffer saline and fixed in 10% buffered 
formalin. The skin sections were embedded in paraffin and microtoned. The sections were stained 
with hematoxylin and eosin and observed under a high power light microscope (40x). The skin 
sections were evaluated for the skin integrity.  
Histopathology of skin samples was carried out at Medicos Centre, Chandigarh-160022, India, 
under the supervision of a trained pathologist. 
Statistical analysis 
All the results are expressed as mean±standard deviation (SD). All statistical analysis was 
performed using graph pad prism 5. Data was analyzed using one-way ANOVA. p-Values < 0.05 
were considered as statistically significant. 
 
Results  
THC-SLNs were prepared successfully by microemulsification method26, which is a spontaneous 
workable method at lab scale, wherein the crystallisation of hot melt lipid occurs in cold water (2-
8 ᵒC), kept under stirring. It is noteworthy to highlight here, that though microemulsions usually 
contain high surfactant (Tween 80) (30% or above) and co-surfactant (5-10%) concentrations39, 
however, the THC-SLNs hydrogel was optimized suitably to meet the specifications laid by 
USFDA for inactive ingredients (Tween 80: 7.50% and phosphatidylcholine: 0.50%). Compritol® 
888 ATO was chosen as the lipid component of the SLNs as it is indicated to result in stable 
dispersions with small particle size40. 
Characterization of THC-SLNs and gel 
Particle size analysis 
Mean particle size of THC-SLNs was estimated to be 96.60 nm with a polydispersity index of 
0.252, indicating a narrow particle size distribution while the mean particle size of blank SLNs 
was found to be 102.40 nm with a polydispersity index of 0.299. It is evident that incorporation of 
THC did not significantly alter the particle size of the nanoparticles. The small particle size 
obtained with both blank and drug loaded SLNs may be attributed to the presence of satisfactory 
surfactant and co-surfactant concentration that results in reduction in the surface tension and 
production of particles with small sizes [41-43].  
Zeta potential 
Zeta potential of THC-SLNs and blank SLNs measured by employing Delsa nano zetasizer at 25 
ᵒC was found to be – 22 mV and -15 mV respectively. High negative charge indicate towards 
formation of a stable nano particulate system with lower chances of aggregation post storage for 
prolonged time period44. The negative charge can be associated with the presence of hydroxyl ions 
on the surface of the lipid nanostructures, and is consistent with the observations in the previous 
studies45.  
TEM 
TEM showed uniform particles in the of size range of 35-175 nm, thus confirming to the size as 
observed by photon correlation spectroscopy (PCS) as given in Figure 1. The particles were 
ellipsoidal in shape with no aggregation and/or irregularity in the structure of the THC-SLNs.  
Total drug content (TDC) and entrapment efficiency (EE) 
TDC of THC-SLNs dispersion and THC-SLNs gel was estimated to be 94.51% ± 2.15% and 
99.68% ± 0.51% respectively. High values of TDC are indicative of the insignificant losses 
incurred during the processes of preparation of THC-SLNs by microemulsification technique46. 
The entrapment efficiency of prepared THC-SLNs and THC-SLNs gel was found to be 69.56% ± 
1.35% and 65.95% ± 0.14%  (n = 6) respectively. Higher EE indicates the suitability of the method 
used for the preparation of SLNs. 
 
pH and Rheology 
The pH value of THC-SLNs gel was found out to be in range of 6.68 ± 0.21, permitting the safe 
use of the gel on the skin. The yield value of the THC-SLNs gel was found to be 13.88 Pa which 
represents its good fluid strength47. The value of n (which indicates the shear thinning or shear 
thickening property of the gel) was less than 1 (n = 0.290), which corroborates the shear thinning 
nature of the THC-SLNs gel48. THC-SLNs gel exhibited consistency index of 77.40 Pa.s, thus 
affirming good spreadability which is a desirable feature of a topical formulation49.  
THC-SLNs gel also displayed fairly good gel strength with a low work of shear, and force of 
extrusion was found to be less than a marketed gel formulation (aceclofenac gel) suggesting the 
ease of extrudability from the collapsible tube. Though stickiness (sign of adhesiveness) was found 
to be less than the marketed formulation yet it was enough to hold the formulation at the site of 
action for a long time. As a comparison with gel was to be made, and in absence of any THC gel 
in the market, aceclofenac gel was used for comparison of rheological properties of the prepared 
SLN hydrogel. 
DSC 
THC (Figure  2A) showed a melting endotherm at 95 ᵒC, which corresponds to its melting point 
with an enthalpy of 126.30 J/g, while Compritol® 888 ATO, (Figure  2B) showed a sharp peak at 
73.06 ᵒC and an enthalpy of 122.60 J/g. THC-SLNs dispersion (Figure  2D), however, showed a 
broad endotherm at a lower temperature starting from 55 oC – 68.8 oC (enthalpy of 54.87 J/g) 
confirming encapsulation of THC into the lipid nanoparticles as no peak was observed 
corresponding to that of THC or lipid whereas distinct peaks at their respective melting points 
were observed in simple physical mixture of Compritol® 888 ATO and THC, (Figure 2C). Also 
melting endotherm of Compritol® 888 ATO in THC-SLNs was depressed as compared to the bulk 
Compritol® 888 ATO suggesting a less stable α or β form of triglycerides in SLNs. This melting 
point depression may be due to their small particle size (nanometer range), high specific surface 
area and the presence of a surfactant. 
XRD 
The X-ray diffraction pattern of pure Compritol® 888 ATO shows sharp peaks at 21ᵒ and 23ᵒ due 
to lipidic polymorphism, Figure  3 represents the crystalline nature of the (A) lipid and the (B) 
drug. Figure  3B also shows distinct peak at 17ᵒ, however upon incorporation of THC into SLNs 
no such peak was observed (Figure  3C), indicating the amorphous nature of the prepared SLNs. 
The amorphous nature is further responsible for the controlled release of the drug from THC-
SLNs50. However, no characteristic peaks in BSLNs indicate the amorphous nature of lipid after 
transformation into SLNs.  
Occlusion testing 
Percentage water loss exclusively depends on the ability of the formulation to form an occlusive 
layer on the skin. There was almost 2 times more percent water loss through the ﬁlter paper at the 
end of 24 and 48 hours for THC-SLNs gel was twice as compared to the Tacroz® Forte. Latter is 
attributed to the high emollient effect of the ointment base of the Tacroz® Forte as compared to 
the THC-SLNs hydrogel. Further, there was no significant difference between the blank SLNs gel 
and THC SLNs gel. The occlusivity offered by THC-SLNs gel and blank SLNs gel could be 
attributed to solid nature of the lipid component which form an intact lipid film on filter paper 
surface. The skin occlusivity offered by THC-SLNs gel would be helpful for mitigating the 
symptoms like itching, dryness and scaling which are the main prompters for induction of 
dermatitis33. In contrast to this, blank Carbopol® 934 gels without any SLNs had lowest occulsion 
factor because of highest water flux due to absence of any lipids in the formulation. This in 
confirmation with previous reports on blank Carbopol® 934 gels33. The occlusion factor measured 
after 24 and 48 hours for THC-SLNs gel, Tacroz® Forte, blank SLNs gel and blank Carbopol® 
934 gel are given in table 2. 
In-vitro drug release 
In vitro drug release studies were performed with the developed THC-SLNs gel, free THC and 
THC-SLNs dispersion (Figure 4A). THC-SLNs dispersion showed a significantly higher and fast 
drug release (p ≤ 0.05) at all evaluation points in comparison to the free drug. The release of THC 
from THC-SLNs gel and SLNs dispersion was almost 16-17 times higher than the free THC 
hydrogel. The release kinetics of THC from THC-SLNs dispersion obeyed Korsmeyer-peppas 
model (non-fickian mechanism) while the drug release pattern from the THC-SLNs gel followed 
Higuchi’s equation indicating the release of drug from hydrogel as a square root of time dependent 
process based on Fickian diffusion51. 
Ex-vivo permeation 
In order to assess the skin permeation and localization of THC from THC-SLNs, the ex-vivo 
permeation ability through porcine ear skin was investigated. The comparative amount of drug 
permeated from all the formulations is given in Figure  4B. The effect of gel as a carrier on 
accumulation and diffusion of THC through the skin was evaluated using ex-vivo skin permeation 
studies. During this study, the permeation data of THC-SLNs gel was compared with free THC 
gel and THC-SLNs dispersion per se. THC-SLNs gel displayed signiﬁcantly higher drug 
permeation at all the sampling times (almost 8.4 fold as compared to free THC gel). A flux value 
of 0.11 ± 0.03 µg/h/cm2 was obtained, with topical application of free THC gel which was 13.75 
times lower than THC-SLNs (1.54 ± 0.42 µg/h/cm2) dispersion and 9.19 times lower than THC-
SLNs gel (1.03 ± 0.33 µg /h/cm2respectively). Permeability coefficient (Kp) obtained for THC-
SLNs was 12.60 times higher than free THC gel while the THC-SLNs hydrogel showed a 8.46 
times higher Kp value in comparison to free THC gel. There was significant difference (p ≤ 0.05) 
in the values obtained for free THC gel and THC-SLNs hydrogel. 
Skin deposition of THC in pig ear skin from THC-SLNs gel was compared with the free THC gel. 
There was a signiﬁcant difference (p ≤ 0.05) in the THC accumulation between the two 
formulations (> 13%). THC-SLNs gel displayed signiﬁcantly higher deposition of drug in the skin 
(202.72 ± 25.45 µg). On the other hand, free THC gel showed depleted deposition of the drug 
(15.04 ± 3.86 µg) in the skin. The quantiﬁcation of drug remaining unabsorbed at the end of 24 
hours showed almost 1.74-fold higher drug on the skin surface in case of free THC gel as compared 
with the THC-SLNs gel. This signifies the importance of incorporating THC into SLNs for 
increasing its penetration as a result of enhanced solubility and small particle size.  
Stability studies 
The THC-SLNs dispersion and the final formulated THC-SLNs gel were stable at various storage 
conditions. There was insignificant change (p ≤ 0.05) in particle size, total drug content and 
entrapment efficiency of THC-SLNs and THC-SLNs gel at 4 ᵒC ± 3 ᵒC, 25 ºC ± 2 ºC/60% RH ± 
5% RH, 40 ºC ± 2 ºC/75% RH ± 5% RH as given in Tables 3A and B. Though increase in the 
particle size was observed, however it was below 200 nm, required for enhanced permeation across 
the stratum corneum52. Latter may be assigned to the fact that on cooling SLNs, lipids are not fully 
crystallized and carbon chains are freezed heterogeneously. With time, carbon chains change their 
orientation and start forming crystals leading to a change in shape of SLNs which exposes new 
surfaces that are not coated with surfactant. These uncoated surfaces which are sticky lead to 
aggregation of SLNs53,33. 
 
Acute dermal irritation studies 
OECD guideline 404 was followed for acute dermal irritation studies34. The formulation was 
applied for 4 hours and was evaluated after 1, 24, 48 and 72 hours of application. No skin reaction 
such as erythema and edema was observed in animals for any group. 
In-vivo pharmacodynamic study 
Excision wound mice model and histopathological study 
The in vivo wound healing potential of the THC-SLNs gel was assessed in comparison with the 
free THC gel using the excision wound mice model54. Representative images of the excision 
wound with the histopathology are depicted in Figure   5 (A1-A10). The positive control (A3 and 
A8) and free THC gel (A4 and A9) demonstrated delayed healing processes compared to naive 
(untreated normal skin) control group (A1 and A6), THC-SLNs hydrogel treated group (A2 and 
A7) and blank SLNs gel (A5 and A10). As compared to the positive control (untreated wounds) 
(A3 and A8), the reduction in wound sizes was significantly higher when THC-SLNs gel (A2 and 
A7) was used. 
The histological study of the skin of positive control animals, Figure  5(A8) shows the absence of 
an intact layer of epidermis and presence of necrotic tissue. Disruption of epidermis, showed 
absence of healing. Visible signs of inflammation in deeper layers i.e., muscles and blood vessels 
were present along with inflammatory exudates, Figure  5(A8 and A1). 
Treatment with THC-SLNs gel shows the intact epidermis and normal dermis with no signs of 
inflammation, Figure 5(A7) as compared to free THC gel, Figure 5(A9). There was an increase in 
the collagenous mass at the site of injury indicating regeneration and repair of the tissue.  
In contrast, immature and disorganized epidermal layers due to delay in full-thickness re-
epithelialisation, fewer and less obvious areas of blood vessels were noted throughout the scantly 
formed granulation tissue of the untreated mice Figure 5(A8). This was further characterized by 
few fibroblasts, less dense collagen fibres. Whereas, more distinct, thick, densely associated and 
well organized collagen fibres/bands with normal fibroblasts alignment and persistence of 
inflammatory cells were found in late granulation tissue of the mice post application of THC-SLNs 
gel, in comparison to free THC gel and blank SLNs gel. 
Biochemical estimation 
LPO 
In positive control mice, there was a significant increase (p < 0.005) in the MDA levels (2.86 
times) as compared to naive mice. In contrast, groups treated with 0.2% w/w of THC-SLNs gel 
and blank SLNs gel, showed a reduction of MDA levels by 60% and 47.60% respectively. 
Furthermore, both these groups produced complete reversal in the elevated MDA levels such that 
the values were similar (p < 0.05) to those obtained for the naïve control groups (Figure  6A). Free 
THC gel however did not show any significant effect on MDA levels. 
Reduced glutathione 
There was a significant reduction (p < 0.05) in GSH levels in positive control (Figure  6B) as 
compared to naïve mice (negative control). Treatment with 0.2% w/w THC-SLNs gel increased 
GSH levels by 2.23 times. However, free THC gel at similar concentrations did not show any 
significant increase in GSH levels.  
SOD assay 
The treatment with THC-SLNs gel significantly increased the SOD level, (Figure  6C) reduces 
oxidative stress and ROS generation which indicates its protective role. SOD levels decreased in 
the positive control group by 9.45 times compared to naive mice. In groups treated with 0.2% w/w 
THC-SLNs gel, SOD levels were increased by 7.60 times. However, 0.2% w/w free THC gel and 
blank SLNs gel did not show any significant increase (p < 0.05) in SOD as compared to the THC-
SLNs gel treated groups. 
Catalase assay 
Catalase levels decreased in the positive control by 2.21 times compared to naive mice (Figure  
6D). In groups treated with 0.2% w/w THC-SLNs gel, catalase levels were increased by 2.02 times. 
However, 0.2% w/w free THC gel did not show any significant increase (p ≤ 0.05) in catalase 
levels as compared to the THC-SLNs group. 
Discussion 
Tetrahydrocurcumin, a stable, hydrogenated product of curcumin has remained as an 
underexplored molecule to be developed as a topical therapeutic for skin inflammation. Nano-
tailoring the molecule can improve its aqueous solubility, permeation and retention onto the 
surface of the skin and can make the molecule bioavailable at the site of application.   
Drug permeation across the skin depends on ability of the drug to diffuse out of the vehicle and its 
penetration through the external cornifying layer (stratum corneum) of the skin55,56. Use of 
phosphatidylcholine to increase drug transport across rat skin has been reported at much higher 
concentration (10-15%) than used in THC-SLNs gel (0.5% PC) so as to meet the Inactive 
Ingredient Guide (IIG) limits specified by Food and Drug Administration (FDA)57. Also, the 
surfactant i.e. Tween 80 is added in accordance to approved IIG limits58. The attained particle size, 
TDC and EE confirmed the suitability of the microemulsification technique for loading white 
curcumin into lipidic nanoparticles. 
TEM examination revealed the existence of particles with ellipsoidal to disc-like shape. DSC and 
X-Ray diffraction studies confirmed the formation of amorphous THC-SLNs. The ideal 
occlusivity offered by THC-SLNs gel was assigned to the ability of lipidic nanoparticles to form 
an adhesive layer upon dermal application and thus occluding the skin surface to avoid the loss of 
water59. As a result, with the enhanced hydration of stratum corneum, the loosening of corneocytes 
packing occurs, which widens the intercorneocyte gap thus facilitating the drug penetration into 
deeper skin strata60. Rheological evaluation of THC-SLNs gel showed appropriate consistency and 
viscosity to adhere and self-immobilize for an easy application on the skin. The results obtained 
in in vitro studies were corroborated with in vivo pharmacodynamic studies. The Higuchian release 
by THC-SLNs gel indicates the pathway of the drug release from the inside of lipid matrix to the 
surface of SLNs and then the outside aqueous phase61.  Ex vivo permeation studies significantly 
showed an approximately 17 times higher flux, indicating the ability of small lipidic nanoparticles 
to cross the skin and reach the site of inflammation. The formulation was non-staining, non-
irritating, non-greasy and easy spreadable as revealed by the acute dermal irritation testing studies 
(OECD 404). This makes the product patient compliant and more acceptable for its use, as 
compared to the topical products of the   parent molecule curcumin which stain the skin on topical 
application. 
The results of the excision wound mice model highlighted that THC-SLNs gel, not only possesses 
anti-oxidant, anti-inflammatory activity but also holds an excellent wound healing potential. 
Owing to accelerated epithelialisation, cellular proliferation, formation of granulation tissue, 
synthesis of collagen tissue, topical application of THC at the wound site produced significant 
wound healing activity, which may be due to its angiogenic potential. These progressive changes 
in the epidermal and dermal architecture include: keratinization and full-thickness epidermal 
regeneration, which covered largely the wound area, intense improvement in the maturation and 
organization of epidermal layers with no debridement crust covering the epidermal surface, an 
increase in deposition and organization of extracellular matrix elements. 
Wound healing was faster and better in the decreasing order: THC-SLNs gel>free THC 
gel>positive control. Wound healing rate was significantly higher (p ≤ 0.05) in THC-SLNs gel 
treated animals than those treated with free THC gel. THC-SLNs gel left no prominent scar at the 
wound site, pointing towards the enhanced bioactivity of THC post incorporation into SLNs62. 
Latter was confirmed by the histological investigations, which revealed a complete healing of skin 
on application of THC-SLNs gel. Similar study reported by Rao et al. (2015) reported the 
usefulness of glucosylated THC in the process of wound healing63. They also confirmed its 
enhanced percutaneous absorption and potent in vivo wound healing effect. Latter study indicated 
the role of glycosyl moiety to improve upon the aqueous solubility of THC which subsequently 
enhances the therapeutic activity of THC. While the bioenhanced activity of THC in our study is 
assigned to the nanocoutured THC which due to the small particle size exhibits enhanced skin 
permeation thus highlighting the significance of incorporating the drug into lipidic nanoparticles33.  
The enhanced antioxidant potential of THC-SLNs gel indicated by a significantly decreased MDA 
(2.22 times), increased GSH (2.23 times), SOD (7.60 times) and catalase (2.02 times) levels vis-
a-vis free THC gel, are a proof to the biochemical in vivo activity post topical application. 
Interestingly, blank SLNs gel also showed some antioxidant properties. This could be due to 
presence of phosphatidylcholine in the SLN formulation. Use of phosphatidylcholine for a long 
duration of time is reported to result in decrease in MDA levels64. Since, phosphatidylcholine 
containing SLNs gel, was applied continuously for a time period of 14 days, it could probably be 
responsible for the observed decreased levels of MDA. Additionally, presentation of 
phosphatidylcholine (2%) as highly bioavailable SLN formulation would have added to its 
efficacy64,65. Similar results have been reported in a study by Kadoma and Fujisawa (2007). They 
revealed that THC oxidized by peroxy radicals may be more antioxidative than curcumin in the 
interplay with GSH66. In another study, THC was reported to be a better molecule for the inhibition 
of phospholipase  A2, a substrate for proinflammatory mediator than curcumin i.e. prostaglandins; 
(which are involved in the process of skin inflammation)66. These in vitro and in vivo studies are 
indicative of the efficacy of THC-SLNs for all the categories of skin ailments. 
To the best of our knowledge, this is the first paper highlighting the therapeutic effectiveness of 
nano-lipidic particles of THC. The in vitro and in vivo studies are indicative of the efficacy of 
THC-SLNs for all the categories of skin ailments with inflammation. This product is expected to 
be a one of its kind with its ability to cater to inflammatory condition of the skin of not only the 
adults but paediatric population as well67. Till now, there are no products available for the chronic 
conditions like dermatitis in the market. The available products belong to the category of steroids, 
antibiotics and calcineurin inhibitors and the use of these products is associated with serious side 
effects68. Thus, THC-SLNs gel would present safer alternative to the currently available products 
in the market and provide ease to the patients with chronic skin inflammation. Further studies are 
necessary to investigate the exact mechanisms related to the findings of the study. Prospective 
studies to confirm the concentration/presence of the THC in the various layers of the skin, which 
include the confocal microscopic studies and dermatokinetic modelling are warranted and planned 
as future protocols. 
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FIGURES 
 
 
Figure 1 Transmission electron microscopy of THC-SLNs. 
 
Figure  2. DSC thermogram of (A) THC (B) Compritol® 888 ATO (C) Physical mixture of 
THC and Compritol® 888 ATO (D) THC-SLNs. 
 Figure 3. XRD pattern of (A) Compritol® 888 ATO (B) Pure THC (C) Blank SLNs (D)THC- 
SLNs . 
 
Figure 4. (A) Percentage cumulative amount released versus time (B) Percentage drug 
permeated versus time. 
 
 Figure 5. Representative images of the excision wound mice model and histopathological 
observations, A1 and A6 shows normal skin, A2 and A7 shows THC-SLNs gel, A3 and A8 
shows positive control, A4 and A9 shows free THC gel, A5 and A10 shows Blank SLNs 
respectively. 
 
Figure  6. Effect of THC-SLNs gel (0.2% w/w), Blank SLNs gel, Positive control, Free THC 
gel, Naïve on (A)  Lipid peroxidation (B) Reduced glutathione levels (C) SOD levels (D) 
Catalase levels in the skin of mice (excision wound).  
*Values are expressed as mean ± SEM (one way ANOVA followed by Tukey test): *p< 0.05 as compared to naïve 
group; #p< 0.05 as compared to positive group; op< 0.05 as compared to Free THC gel group. 
TABLES 
Table 1. Grouping of animals in excision wound mice model. 
S.no. Group Treatment (n = 6) 
1 Test THC-SLNs gel  
(0.2% w/w) 
2. Positive Control No treatment 
3. Free THC gel Free THC gel  
(0.2% w/w) 
4. 
5. 
Naive Control 
Blank gel 
Untreated normal skin 
Blank SLNs gel 
 
 
Table 2.  Occlusion factor measured after 24 and 48 hours for THC-SLN gel, Tacroz® Forte, 
blank SLNs gel and blank gel without SLNs. 
S.no. Time (h) Occlusion Factor (F) 
  
THC-SLNs  gel Tacroz® Forte Blank SLNs gel Blank Gel 
without SLNs 
  
    
1 24 76.67 ± 1.02 88.83 ± 2.32 75.62 ± 2.45 18.68 ± 1.30 
2 48 82.88 ± 1.08  1.64 ± 3.27 81.89 ± 2.15 23.16 ± 1.10 
 
 
 
 
 
 Table 3A. Stability studies of THC-SLNs. 
Time 
(months) 
THC-SLNs 
 
 4 ᵒC 40 ᵒC 
Particle 
size 
(nm) 
Total drug 
content (%) 
Entrapment 
efficiency (%) 
Particle 
size 
(nm) 
Total drug 
content (%) 
Entrapment 
efficiency (%) 
0 119.9 94.213 ± 0.058 69.450 ± 0.135 119.9 94.213 ± 0.058 69.450 ± 0.135 
1 131.1 94.187 ± 0.104 69.014 ± 0.047 152.3 93.980 ± 0.151 68.657 ± 0.111 
2 144.4 93.676  ± 0.120 69.125 ± 0.124 173.3 93.649 ± 0.183 68.584 ± 0.027 
 
 
Table  3B. Stability studies of THC-SLNs gel. 
Time 
(months) 
THC-SLNs gel 
 25 ᵒC 40 ᵒC 
 Total drug 
content (%) 
Entrapment 
efficiency (%) 
 Total drug 
content (%) 
Entrapment 
efficiency (%) 
0 99.58 ± 0.120 68.95 ± 0.128 99.58 ± 0.500 68.95 ± 0.145 
2 98.13 ± 0.186 67.65 ± 1.03 98.00 ± 1.21 66.91 ± 0.231 
* extended stability studies are in progress for the final product as well as for THC-SLNs 
dispersion at both 4 ᵒC, 25 ᵒC and 40 ᵒC. 
 
